Company intelligence / Profile preview

Boost Capital

Copenhagen, Denmark

Ownership: Private
Development stage: Other

Overview

BT-101 showed positive topline results in Phase I/II BOOSTB4 trial (Sep 2024). Positive FDA pre-IND meeting (Nov 2024) with full acceptance of proposed clinical development plan. Preparing for pivotal Phase III study in US and Europe.

Therapeutic areas: Rare Diseases
Modalities: Cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Boost Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boost Capital.

Explore the full profile